Compare REFR & OSRH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | REFR | OSRH |
|---|---|---|
| Founded | 1965 | N/A |
| Country | United States | United States |
| Employees | N/A | 22 |
| Industry | Multi-Sector Companies | |
| Sector | Miscellaneous | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.6M | 17.9M |
| IPO Year | 1995 | N/A |
| Metric | REFR | OSRH |
|---|---|---|
| Price | $0.42 | $0.45 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 39.9K | ★ 686.5K |
| Earning Date | 05-07-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,488,642.00 | N/A |
| Revenue This Year | N/A | $9.30 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.35 | $0.30 |
| 52 Week High | $2.70 | $1.24 |
| Indicator | REFR | OSRH |
|---|---|---|
| Relative Strength Index (RSI) | 20.71 | 50.26 |
| Support Level | N/A | $0.40 |
| Resistance Level | $1.02 | $0.45 |
| Average True Range (ATR) | 0.06 | 0.04 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 16.36 | 43.44 |
Research Frontiers Inc is engaged in the development and marketing of technology and devices to control the flow of light. The company develops and licenses its patented suspended particle device light-control technology to other companies that manufacture and market the SPD-Smart chemical emulsion, the light-control film made from the chemical emulsion, the light-control panels made by laminating the film, electronics to power end-products incorporating the film, or lamination services for, and the end-products. The company's revenue source comes from the licensing of technology.
OSR Holdings Inc is a healthcare company dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of potentially transformative therapies and healthcare solutions. The business of the company includes developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention medical device and systems distribution in Korea. The company's pipeline products include: Vaximm, Darnatein, Woori IO, and RMC.